ABSTRACT
INTRODUCTION
Proliferation, differentiation, and apoptosis of normal and leukemic hematopoietic stem cells are partially regulated by external signals received from chemokines and cytokines and by interactions with the local microenvironment. The response to these signals is, in turn, transmitted from the cell surface to the nucleus through the extensive series of signal transduction pathways (STPs), including the JAK/STAT, RAS/Raf/MEK/ERK, and PI3K/AKT pathways. 1 There is extensive cross-talk and cross-activation between these pathways, so that the activation of one pathway often leads to the activation of others. (See figure 1 .) The disruption of normal signaling through these pathways, occurring as a result of either the mutation of pathway components or alterations in the internal and external (from chemokines, cytokines, or stroma) signals received, is thought to contribute to leukemogenesis by perturbing the rates of proliferation, differentiation, and apoptosis. [1] [2] [3] The functional effects of modulating the expression and/or activation of STP proteins have been evaluated in leukemia cell lines and primary leukemia samples.
One of these pathways, the PI3K/AKT pathway, has been extensively studied in normal and malignant cells. The pathway is activated when threonine 308 is phosphorylated by PDK1
and serine 473 (thought to be more crucial for full activation) is phosphorylated by PDK2.
Indeed, constitutive phosphorylation at serine 473 was found in 21 of 22 samples from AML patients with high blast counts and was an adverse prognostic factor for survival among 55 patients with AML. 4 Phosphorylated AKT (pAKT), in turn, phosphorylates Bad, NF-κB, GSK/β-catenin, mTOR, caspases, and waf1, resulting in increased glucose flux and cell proliferation, and protection against apoptosis. 1 In two studies, activated AKT was observed to promote leukemogenesis in nontransformed hematopoietic precursors. 5, 6 Conversely, in short-term
For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From cultures of cells from 10 cases of primary AML with high blast percentages, the blockade of AKT phosphorylation by LY294002 decreased cell survival and significantly reduced clonogenic cell growth by inducing apoptosis, 7, 8 while other AKT inhibitors have been shown to slow the progression of tumors. 9 The RAS/Raf/MEK/ERK pathway is a key STP that has been demonstrated to result in increased cell proliferation, differentiation, and survival; angiogenesis; and metastasis. 1, 10 Activation of this pathway has been demonstrated in numerous human malignancies, including leukemia. 1, [10] [11] [12] We have demonstrated that conditional activation of this pathway in murine hematopoietic cells results in an AML-like phenotype. 13 Mutations of upstream RAS and Raf are frequent, but mutations in MEK and ERK are uncommon, suggesting that activation of this pathway is triggered by changes elsewhere in the cell 1 possibly including changes in the level or function of ERK phosphatatses including PAC1 12 and MKP-1. 14 Conversely, the blockade of ERK activation in leukemia cell lines was observed to result in cell death and, when combined with chemotherapy, to synergistically increase cell kill. [15] [16] [17] [18] In a retrospective study, we have demonstrated that the constitutive activation of ERK in primary AML samples is common and an adverse prognostic feature. 19 Elegant studies utilizing conditionally active kinase constructs indicate a requirement for the activation of the PI3K pathway during MEK-mediated transformation of certain hematopoietic cells 20 and provide evidence that expression of activated Raf/MEK/ERK and PI3K/Akt pathways could synergize and result in the abrogation of cytokine dependence of hematopoietic cells. 21 PKCα is a member of a family of cytoplasmic serine/threonine kinases with varying dependence on phospholipids and Ca 2+ as cofactors and is widely expressed in normal tissue, including myeloid cells. 22, 23 PKCα must also be phosphorylated to be activated, and this is
For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From triggered by many growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor and epidermal growth factor, and by phorbol esters, phosphatidylserine, and diacylglycerol and has numerous interactions with the STPs, thereby regulating diverse cellular responses, including proliferation, differentiation, and apoptosis. 22 It has been implicated in malignant transformation, and indeed, it is expressed at elevated levels in many human tumors. 22, 24 In fact, we have previously demonstrated that high levels of PKCα were an adverse prognostic factor for patients with AML. 25 In B-cell chronic lymphocytic leukemia, PKCα activation decreased chemosensitivity, and its inhibition induced apoptosis. 26 Conversely, the inhibition of PKCα activity caused decreased phosphorylation and activation of ERK1/2, resulting in decreased cell survival and increased levels of apoptosis.
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In general, the level of activation of each of these pathways has been ascertained in only small cohorts of patients, and these studies have not determined the activation state of the other other STPs. This would imply that therapeutic agents targeting single pathways that are being developed may be deemed clinically ineffective 1, 10, 22 . To learn more about the simultaneous activation of STPs, we studied the level of expression and the activation status of three of these pathways by measuring PKCα, ERK2 and pERK2, and AKT and pAKT in a prospective fashion in samples from patients with primary leukemia. The prognostic impact of each protein was evaluated individually, and the combined prognostic impact of the activation of multiple pathways was also investigated. We observed that these pathways are activated in most cases of
For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From leukemia, that the simultaneous activation of multiple pathways is common, and that the prognosis worsens as more STPs are activated.
MATERIALS/METHODS

STUDY GROUP
Peripheral blood or leukopheresis specimens or bone marrow specimens were collected prospectively from patients with newly diagnosed AML evaluated at The University of Texas M. were treated with a traditional idarubicin and standard dose ara-C (3+7) regimen. All three APL patients received ATRA containing regimens. Mylotarg was used alone or in combination in 8.5% and other investigational agents (DAC, SAHA, Zarnestra etc) were used in 6.3%, with all of these patients being older than 68 yrs. Stem cell transplant was performed in 32 cases (allogeneic =22, matched unrelated donor =10), including 6 primary refractory, 5 first remission and 21 after first relapse or in second remission.
SAMPLE PROCESSING
For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From Samples were placed on ice immediately after collection and were processed fresh within two hours of collection to generate a leukemia cell-enriched fraction by isolating the mononuclear cell fraction by Ficoll-Hypaque separation (Mediatech, Hearndon,VA) followed by the depletion of CD3+/CD19+ B-and T-cells by magnetic antibody-conjugated sorting (Miltenyi Biotec, Auburn, CA), as previously described. 28 The cells were used fresh to make whole-cell lysates for
Western blotting.
WESTERN IMMUNOBLOTTING ANALYSES
Western immunoblotting analyses were performed using material from 4.5x10 5 cells and the Biorad Criterion system (Biorad, Hercules, CA), with bone marrow and peripheral blood samples loaded on the same blot with control cell lines (K562 and Jurkat cells) and molecularweight markers as previously described. 28 Assays for AKT and pAKT were added after analysis of several apoptosis and STP proteins had already been performed and insufficient material remained to measure these proteins in 42 cases.
Triplicate membranes were created for each sample. The first blot was probed with antipERK2 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, at a 1:1000 dilution) and anti-BCL2 and then stripped and reprobed for total AKT (Cell Signaling Technologies, Beverly, MA, at a 1:1000 dilution). The second blot was initially probed for pAKT (Cell Signaling, Technologies, Beverly, MA, at a 1:1000 dilution) and then stripped and reprobed for total ERK2 using a monoclonal antibody (Santa Cruz Biotechnology, at a 1:1000 dilution). The third blot was probed for PKC-α (1:500) (Santa Cruz Biotechnology) and Bax (Cell Signaling Technologies, at a 1:1000 dilution) and then stripped and reprobed for actin (Sigma-Aldrich, St.
Louis, MO, at a 1:2000 dilution). Because antibodies that specifically recognize only pPKCα
were not available when this study was initiated, we studied total PKCα instead.
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STATISTICAL ANALYSIS
Pairwise associations between patients' covariates were assessed by performing two-sample t- Pearson correlation was used to assess correlation between protein expression. If pathway crossactivation were occurring, then the frequency of cases with multiple pathway activation would be expected to be higher than expected based on the frequency of individual pathway activation (Freq high-PKCα *Freq high-ERK2&pERK2 *Freq high-pAKT ). To assess this, patients were grouped according to whether they had no, one, two, or three pathways activated and the chi-square test was utilized for comparing the frequency of events. Unadjusted survival and remission duration analyses were performed using Kaplan-Meier plots. 31 Unadjusted comparisons of survival between patient subgroups were made using the logrank test. 32 The Cox proportional hazards model 33 and its generalizations 34 using stepwise logistical regression were used to assess the ability of the treatment indicators, including PKCα, ERK2 and pERK2, AKT and pAKT, and other patient characteristics, to independently predict survival. Variables were selected for inclusion in the model if they had previously been recognized as important prognostic factors [35] [36] [37] and there was evidence of their association with survival in this population. The final model was obtained by performing backward selection with a p-value cutoff of 0.05. All computations were carried out using Statistica version 6 software (StatSoft Inc, Tulsa, OK).
RESULTS
Peripheral blood or leukopheresis specimens (N=118) and bone marrow specimens (N=108)
were collected from patients with newly diagnosed acute myelogenous leukemia during the study period. Simultaneous blood and marrow specimens were available from 37 of these patients.
Previous analysis of this same sample set had shown that the mean expression levels and the range of expression and of these same proteins, determined in leukemia cell-enriched fractions were statistically identical regardless of whether the source is blood or marrow. 28 Consequently, the data for marrow and blood samples were pooled for this analysis, with the blood sample utilized whenever both blood and marrow samples were available (the total blast yield from blood samples generally exceeds that from marrow samples, so the use of blood samples permits analysis of more proteins from the same sample). Demographic and clinical details for the 188 patients are shown in Table 1 . The prognostic impact of each protein was evaluated individually and in combination reflecting the activation of multiple pathways. weeks; p= 0.11). The adverse effect of high levels of ERK was more prominent in patients lacking high pERK expression (See Table 2 and Figure 2 ). Since both high ERK2 and pERK2 levels were adverse prognostic factors, generating a ratio of pERK2 to ERK2 obscured their prognostic relevance. In contrast, creating four groups on the basis of whether both were low in comparison with groups in which one or both were high revealed that survival was best in patients with low levels of both and similar in patients with high levels of one or both (72, 39, and 30 weeks for those with no, one, or both high (ERK2 and pERK2), respectively; p=0.012)
EXPRESSION OF ERK AND pERK2 ARE ADVERSE PROGNOSTIC FACTORS IN AML
EXPRESSION OF HIGH LEVELS OF PKCα IS AN ADVERSE PROGNOSTIC FACTOR IN AML
In our prior retrospective study, we observed a trend toward an inferior prognosis in patients with high levels of total PKCα . 25 Our observations in the present study were very similar, in that the CR rate was lower in patients whose AML cells expressed high levels of PKCα (49% vs. 60%; p=0.14), the relapse rates tended to be higher (63% vs. 51%; p=.21), and the CR duration was somewhat shorter (45 vs. 50 weeks; p=0.1), which together resulted in a lower overall median survival duration (34 vs. 60 weeks; p = 0.02), as shown in Table 2 and Figure 3 .
TOTAL AKT LEVELS ARE NOT PROGNOSTIC IN AML
The total AKT levels did not prove to be a prognostic factor for remission, CR duration, or survival (p=0.78).
HIGH LEVEL OF pAKT IS AN ADVERSE PROGNOSTIC FACTOR IN AML
pAKT was not detected in 9% of the patient samples and was weakly, moderately, and strongly expressed in 27%, 38%, and 32% of the samples, respectively. When patients were dichotomized into two groups according to the median level of expression, patients with low levels of pAKT had somewhat better CR rates (60% vs. 50%; p= 0.21), longer median CR durations (71 vs 32 week; p= .13), and statistically significant longer median survival times (59 vs. 30 weeks; p= 0.02) compared with those with high levels of pAKT (Table 2 and Fig. 4 ).
MULTIPLE PATHWAY ACTIVATION IS MORE FREQUENT THAN EXPECTED
If pathway cross-activation is occurring, then the frequency of cases with multiple pathway activation would be expected to be higher than expected based on the frequency of individual pathway activation (Freq high-PKCα *Freq high-ERK2&pERK2 *Freq high-pAKT ). The expected and observed frequencies for each possible combination and of having 0, 1 2 or 3 pathways activated is shown in table 3. In this data set, the observed/expected ratio for having all three pathways activated was 1.67 and for having no pathways activated was 1.9 (χ 2 = 23.3, p=0.00004), strongly suggesting that cross-activation was occurring. Of note, there was no significant correlation between the level of expression of any of these proteins when compared individually (Table 4) .
FLT3 ABNORMALITIES ARE NOT ASSOCIATED WITH INCREASED STP ACTIVATION
Since these STP are downstream of FLT-3 the presence of a FLT-3 ITD or mutation might correlate with STP activation status. The presence of the FLT3-ITD or FLT3-D835 mutation (routinely assessed at diagnosis) was found in 27 and 7 of 101 cases, respectively, but did not correlate with the level of ERK, pERK, PKCα, or pAKT; however, the level of total AKT tended to be higher among patients with either mutation than in those lacking both mutations (P=0.09).
Similarly, the distribution of patients with none, 1, 2, or 3 STP activated did not differ based on FLT-3 status (χ 2 =.43, P=0.93).
PROGNOSIS WORSENS WITH INCREASING ACTIVATION OF MULTIPLE SIGNALLING PATHWAYS
When patients were grouped according to whether they had no, one, two, or three pathways activated, prognosis proved to be worse for those patients who had multiple pathways activated (Fig. 5) , with a median survival of 24, 42, and 58 weeks in those with three, two, and one pathway activated, respectively; the median was not reached in those who had no pathway activated (59% alive beyond 78 weeks) (p=0.01).
Univariate and multivariate analyses, with survival as the endpoint, were conducted using traditional prognostic factors and terms for low or high PKCα, ERK2 and pERK2, pAKT, and the combination variable PKCα-ERK2&pERK2-pAKT. As expected, in the univariate analysis ( 
DISCUSSION
We conclude from our data that activation of the STP components PKCα, pERK2, and pAKT is very frequent in AML and that each has an adverse prognostic impact that is significant and independent of the traditional prognostic factors age, PS, and cytogenetics. The statistically significant difference in survival arises from the combined effect of non-significant trends for lower remission rates, shorter remission durations and higher relapse rates observed in patients with STP activation. The higher-than-expected frequency of the concurrent activation of either all pathways or none of the pathways demonstrates that there is cross-activation of the pathways when STPs are activated. The importance of this is suggested by the more adverse prognosis in patients whose AML have all three pathways activated. Since activation of individual STP has been reported in numerous types of malignancies it is highly likely that these observations may generalize to other types of cancer beyond AML.
There were several advantages of our study. First, the large number of patients analyzed in this prospective study (146 for AKT) significantly exceeds the 55 patients analyzed by Min et al, 4 and the 188 cases for which PKCα and ERK2 were analyzed in this study complements our similarly sized retrospective studies. In addition, to our knowledge, this is the first time that multiple STP activation has been shown to confer a more adverse prognosis than the isolated activation of a single STP.
The question immediately arises regarding the nature of the observed activation of multiple STP. Analysis of the spectrum of mutations identified in human leukemias has indicated that activating kinase mutations that confer a proliferative and/or survival advantage to
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Possible scenarios include mutations in phosphatases which commonly control activation of several signaling pathways; aberrant expression and/or mutation(s) in recently discovered microRNA (miRs), such as let-7 39 ; and activation of STP in response to micro environmental and identification of such critical pro-survival targets, guiding in constructing mechanism-based combinations of signal transduction-related therapies.
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A potential limitation of our study was that we looked at PKCα levels instead of pPKCα levels because pPKCα antibodies were not available when the study started. However, using a pPKCα antibody with high specificity (Upstate Biologicals, Charlottesville, VA) that recently became available, we performed Reverse-Phase Protein Array (RPPA) experiments and probed 90 of the specimens from patients in the present study for pPKCα. 53 This showed a very high correlation between pPKCα levels and total PKCα levels, and confirmed the prognostic impact 1 Variables that were analyzed but found to be non-significant at the p=0.05 level in univariate analysis included chemotherapy treatment protocol, continuous or categorized white blood cell count, hemoglobin, platelet count, percentage of blood blasts, percentage of marrow blasts, percentage of cells CD34 positive by flow cytometry, serum bilirubin, fibrinogen, fibrin split products, D-dimers, calcium, prothrombin time, activated partial thomboplastin time, sample source (blood vs marrow, p=.47), and diagnosis date, or sample date, the latter two of which were included as controls. 2 Variables listed in this column were shown to be significant by univariate analysis but were not significant when added back one at a time into the final model consisting of these variables: age, performance status, favorable cytogenetics, and unfavorable cytogenetics. The p value shown is for the addition of that parameter alone to the aforementioned four parameters. 3 Stem Cell Transplant is not significant if the dataset is limited to a population similar to those that underwent transplant, i.e. those <67 years of age and surviving >20 weeks. Since SCT is not a variable available for consideration at diagnosis it was not included in the final model using variables available at the time of diagnosis. The multivariate results do not change significantly if SCT is included, with the combination terms having similar statistical significance, but the term for age dropping out of the final models. For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From
